Hybio Pharmaceutical Co., Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Hybio Pharmaceutical Co., Ltd.?

Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by Hybio Pharmaceutical Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, from Feb 9, 2026 to Jun 30, 2026. 1 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Shenzhen
FEI numbers on the lines
3026377169
Refused lines
2
Lines with an Import Alert 66-80 API or powder code
1
Drugs named in the product codes
Semaglutide, Tirzepatide
Refusal dates
Feb 9, 2026 to Jun 30, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Hybio Pharmaceutical Co., Ltd. is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Jun 30, 2026China61PBY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
8NP-0146038-9/10002/1
Feb 9, 2026China61PDR74 TIRZEPATIDE (ANTI-DIABETIC)NonSterile PowderFRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.799-2538313-8/10003/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.2
NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).1
DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.1

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 46 products naming liraglutide, semaglutide and tirzepatide under the labeler name “Hybio Pharmaceutical Co., Ltd.”, “Hybio Pharmaceutical Co. Ltd” and “Hybio Pharmaceutical Co., Ltd”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (26); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (20).

14403-0021Hybio Pharmaceutical Co., Ltd.Not givenLiraglutidePOWDERNot given1 mg/mgBULK INGREDIENTJun 16, 2025None givenDec 31, 2026Unfinished drugs
14403-0021Hybio Pharmaceutical Co., Ltd.Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 12, 2025None givenDec 31, 2026Unfinished drugs
14403-0021Hybio Pharmaceutical Co., Ltd.Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 12, 2025None givenDec 31, 2026Unfinished drugs
14403-0021Hybio Pharmaceutical Co., Ltd.Not givenLiraglutidePOWDERNot given1 g/gBULK INGREDIENTDec 12, 2025None givenDec 31, 2026Unfinished drugs
14403-0018Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTApr 6, 2024None givenDec 31, 2026Unfinished drugs
14403-0018Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTOct 13, 2025None givenDec 31, 2026Unfinished drugs
14403-0018Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTDec 12, 2025None givenDec 31, 2026Unfinished drugs
14403-0018Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGApr 28, 2024None givenDec 31, 2027Unfinished drugs
14403-0018Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGApr 28, 2024None givenDec 31, 2027Unfinished drugs
14403-0018Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGDec 12, 2025None givenDec 31, 2027Unfinished drugs
14403-0018Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGApr 28, 2024None givenDec 31, 2027Unfinished drugs
14403-0024Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTSep 4, 2025None givenDec 31, 2026Unfinished drugs
14403-0024Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTDec 12, 2025None givenDec 31, 2026Unfinished drugs
14403-0024Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGFeb 5, 2026None givenDec 31, 2027Unfinished drugs
14403-0024Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMay 6, 2026None givenDec 31, 2027Unfinished drugs
14403-0024Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMay 6, 2026None givenDec 31, 2027Unfinished drugs
14403-0024Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMay 6, 2026None givenDec 31, 2027Unfinished drugs
14403-0024Hybio Pharmaceutical Co. LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGMay 7, 2026None givenDec 31, 2027Unfinished drugs
14403-0018Hybio Pharmaceutical Co., LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTApr 28, 2024None givenDec 31, 2026Unfinished drugs
14403-0024Hybio Pharmaceutical Co., LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGSep 17, 2026None givenDec 31, 2027Unfinished drugs
14403-0024Hybio Pharmaceutical Co., LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGSep 18, 2026None givenDec 31, 2027Unfinished drugs
14403-0030Hybio Pharmaceutical Co., LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGSep 22, 2026None givenDec 31, 2027Unfinished drugs
14403-0030Hybio Pharmaceutical Co., LtdNot givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGSep 22, 2026None givenDec 31, 2027Unfinished drugs
14403-0024Hybio Pharmaceutical Co., Ltd.Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENTDec 12, 2025None givenDec 31, 2026Unfinished drugs
14403-0030Hybio Pharmaceutical Co., Ltd.Not givenSemaglutidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGOct 16, 2026None givenDec 31, 2027Unfinished drugs
14403-0017Hybio Pharmaceutical Co. LtdNot givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTMar 28, 2024None givenDec 31, 2026Unfinished drugs
14403-0029Hybio Pharmaceutical Co. LtdNot givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGSep 16, 2026None givenDec 31, 2027Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTApr 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTApr 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTApr 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 26, 2024None givenDec 31, 2027Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 26, 2024None givenDec 31, 2027Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 26, 2024None givenDec 31, 2027Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 26, 2024None givenDec 31, 2027Unfinished drugs
14403-0017Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDINGJun 26, 2024None givenDec 31, 2027Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 kg/kgBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTApr 1, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0020Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJun 26, 2024None givenDec 31, 2026Unfinished drugs
14403-0027Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTOct 13, 2026None givenDec 31, 2027Unfinished drugs
14403-0028Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJan 23, 2026None givenDec 31, 2027Unfinished drugs
14403-0028Hybio Pharmaceutical Co., Ltd.Not givenTirzepatidePOWDERNot given1 g/gBULK INGREDIENTJan 23, 2026None givenDec 31, 2027Unfinished drugs

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

2 lines from FDA files read Nov 15, 2026.